Research programme: sodium ion channel modulators - Purdue Pharma
Alternative Names: NaV1.7 ion channel modulators - Purdue PharmaLatest Information Update: 17 Jun 2026
At a glance
- Originator Purdue Pharma
- Developer AnaBios Corporation; Purdue Pharma
- Class Non-opioid analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 01 May 2026 Discontinued for Pain in USA (unspecified route) (Purdue Pharma website, June 2026)
- 28 Oct 2019 No recent reports of development identified for research development in Pain in USA
- 05 Dec 2016 Purdue license the rights to a suite of patents for NaV1.7 sodium ion channel blockers to AnaBios